share_log

Lake Street Maintains Buy on Ensysce Biosciences, Adjusts Price Target to $8 - 1-for-20 Reverse Stock Split

Benzinga Real-time News ·  Nov 17, 2022 10:08

Lake Street analyst Thomas Flaten maintains Ensysce Biosciences (NASDAQ:ENSC) with a Buy, adjusts price target to $8 - 1-for-20 reverse stock split.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment